BioSphere Medical, Inc. (NASDAQ:BSMD) (“BioSphere” or the
“Company”) – the pioneer in the use of bioengineered
microspheres to treat uterine fibroids, hypervascularized tumors
and vascular malformations by a minimally invasive, image-guided
medical procedure called embolotherapy – today reported financial
results for the three and nine months ended September 30, 2009.
Highlights of the third quarter of 2009 and subsequent weeks
include:
- Net loss per share was $0.02
during the third quarter of 2009, sharply narrowed from a net loss
per share of $0.09 in the third quarter of 2008
- Total worldwide revenue was
$7.69 million for the third quarter of 2009, an increase of 7% over
the same period in 2008
- Total U.S. revenue was $6.00
million, unchanged from the same period in 2008
- Total outside the United States
(OUS) revenue was $1.69 million, an increase of 42% over the same
period in 2008
- The Company submitted an
Investigational Device Exemption (IDE) with the U.S. Food and Drug
Administration (FDA) for a pivotal trial of its QuadraSphere®
Microspheres loaded with doxorubicin for the treatment of primary
liver cancer
- Leading peer-reviewed scientific
journals continue to support uterine fibroid embolization (UFE) as
a Level A, American College of Obstetrics and Gynecology
(ACOG)-recommended, treatment option for uterine fibroids
Commentary
Richard Faleschini, BioSphere’s president and chief executive
officer, said, “Our momentum during the quarter in interventional
oncology culminated in the recent submission of our IDE for a
pivotal study using QuadraSphere loaded with doxorubicin for the
treatment of primary liver cancer. We view this study as being
strategically important to the Company and to the field of
oncology. Only about 25% of the more than 600,000 patients
diagnosed each year with hepatocellular cancer worldwide can be
treated with surgical resection or a liver transplant. For the
majority of patients with hepatocellular cancer, conventional
chemoembolization, or TACE, is a standard of care. Independent
studies in Europe of our embolic loaded with doxorubicin have
generated positive results, and the IDE study is designed to
further evaluate clinical performance. Positive outcomes in the
QuadraSphere with doxorubicin clinical trial would be an important
milestone for BioSphere. If the trial is successful and we obtain
FDA approval of our premarket approval application, ours would be
the first FDA approval of a device to treat hepatocellular
carcinoma using drug-eluting chemoembolization, further
demonstrating our leadership position in embolotherapy platform
technologies.”
“We believe that U.S. sales of Embosphere® Microspheres for UFE
during the quarter reflect the nationwide, sequential-quarter
slowdown in certain elective medical procedures, in part due to
high unemployment in the United States plus usual third quarter
seasonality. Our marketing initiatives are showing increased
activity and results as planned for in the second half of the year,
but are not yet enough to overcome these other factors,” Mr.
Faleschini added. “We were very pleased by the publication of a
third-party study in the October 2009 issue of the Journal of
Vascular Interventional Radiology, in which the authors concluded
that uterine artery embolization is superior to the laparoscopic
occlusion of uterine arteries employing Endoclips. We believe that
the results of this study further support the August 2008 Level A
recommendation of UFE by ACOG, and are additive to the large body
of data that show UFE to be an excellent therapeutic alternative
for properly selected women with symptomatic fibroids.”
“We were also very happy to see an article published in the New
York Times on October 13 by the well-known health writer Jane Brody
in which she discussed treatment options for uterine fibroids and
said of uterine fibroid embolization, ‘this nonsurgical procedure
is perhaps the most viable alternative to a hysterectomy for women
who have completed childbearing.’ We believe that this growing
awareness among practitioners and women bodes well for the
long-term growth of UFE,” Mr. Faleschini concluded.
Financial
Results
Total worldwide revenue for the third quarter of 2009 was $7.69
million, an increase of 7%, compared with $7.20 million for the
third quarter of 2008. Worldwide revenue from sales of embolics and
delivery systems for the third quarter of 2009 was $7.50 million,
up 6% from $7.08 million in the prior year. Revenue from licensing
and a milestone payment under the Nippon Kayaku distribution
agreement was $0.19 million, compared to $0.10 million in the same
period last year.
U.S. sales of embolics and delivery systems were $5.89 million
in the third quarter of 2009, relatively unchanged from $5.90
million in the third quarter of 2008. Revenue from embolics and
delivery systems in Europe, and the Middle East and Africa (EMEA)
in the third quarter of 2009 was $1.12 million, an increase of 11%
(16% in local currency), compared with $1.01 million for the same
period in 2008. In markets outside of the United States and EMEA,
product revenue was up more than 200% to $0.49 million for the
third quarter of 2009, compared with $0.16 million for the same
period in 2008. The People’s Republic of China and Brazil accounted
for much of the increase, with combined revenues of $0.36 million,
compared with $0.02 million in the comparable quarter last
year.
Gross profit rose to $5.84 million, or 75.9% of revenue, for the
third quarter of 2009, compared with gross profit of $5.31 million,
or 73.8% of revenue, for the third quarter of 2008. The gross
profit margin improvement reflects higher non-product revenue and
increased manufacturing efficiencies.
Operating expense for the third quarter of 2009 was $6.53
million, compared with $6.93 million for the third quarter of 2008.
The decrease was primarily due to lower marketing expenses in the
U.S. and Europe.
Operating loss for the third quarter of 2009 declined
significantly, to $0.70 million from $1.63 million in the same
period of 2008.
Net interest income for the second quarter of 2009 was
negligible, compared with net interest income of $0.09 million for
the third quarter of 2008, reflecting the near-zero interest rate
on treasury securities, which make up the majority of the Company’s
investment portfolio. Foreign exchange loss and other expense for
the third quarter of 2009 was $0.13 million, primarily due to the
weakening of the U.S. dollar against the euro during the third
quarter of 2009, compared with a foreign exchange gain for the
third quarter of 2008 of $0.27 million due to the strengthening of
the U.S. dollar against the euro in that period.
The Company recorded an income tax benefit of $0.61 million, or
$0.03 per share, from the French economic stimulus program during
the third quarter of 2009, compared with an income tax provision of
$0.13 million in the same quarter last year.
The quarterly preferred stock dividend for the third quarter of
2009 was $0.15 million, unchanged from the third quarter of
2008.
Net loss applicable to common stockholders for the third quarter
of 2009 was $0.36 million, or $0.02 per share, an improvement of
77% when compared with a net loss applicable to common stockholders
of $1.54 million, or $0.09 per share, in the same period last
year.
As of September 30, 2009, BioSphere had cash, cash equivalents
and marketable securities of $18.57 million, up $0.87 million from
$17.70 million at June 30, 2008 and up $0.33 million from $18.24
million at December 31, 2008. In the third quarter of 2009,
BioSphere generated positive operating cash flow of $0.96
million.
Sales by therapeutic area in the third quarter of 2009 were as
follows:
- Worldwide sales of embolics used
in interventional gynecology, or UFE, were $5.52 million,
relatively unchanged from $5.56 million in the third quarter of
2008, which includes U.S. sales of $4.54 million, a decline of 5%,
and sales outside of the U.S. of $0.98 million, an increase of
22%.
- Worldwide sales of embolics used
in interventional oncology rose 31% to $1.60 million compared with
the third quarter of 2008, which includes U.S. sales of $1.13
million, an increase of 20%, and sales outside of the U.S. of $0.47
million, an increase of 69%, with the bulk of this increase coming
from the People’s Republic of China.
- Worldwide sales of delivery
systems were $0.38 million, compared with $0.30 million in the
third quarter of 2008, which includes U.S. sales of $0.22 million
and sales outside of the U.S. of $0.16 million.
For the nine months ended September 30, 2009, total revenue was
$23.08 million, compared with $22.02 million in the prior-year
period, an increase of 5%. Revenue excluding gastric products was
$23.08 for the current period, compared with $21.23 million for the
same period last year, an increase of 9%, or 11% in constant
currencies. Net loss applicable to common stockholders was $2.81
million, or $0.16 per share, compared with $4.39 million, or $0.24
per share, in the nine months ended September 30, 2008.
Conference Call and Webcast
The Company will host a conference call to discuss these results
and answer questions on October 29, 2009 beginning at 8:30 a.m.
eastern time. The dial-in number is 1-888-563-6275 (U.S./Canada) or
1-706-643-3137 (International), and the conference ID is 37021211.
The live webcast will be available in the “Investors” section of
BioSphere’s Web site at www.biospheremed.com. A replay of the
webcast will also be available at BioSphere’s Web site.
About BioSphere Medical, Inc.
BioSphere Medical, Inc. seeks to pioneer and commercialize
minimally invasive diagnostic and therapeutic applications based on
proprietary bioengineered microsphere technology. The Company's
core technologies, patented bioengineered polymers and
manufacturing methods, are used to produce microscopic spherical
materials with unique beneficial properties for a variety of
medical applications. BioSphere's principal focus is the use of its
products for the treatment of symptomatic uterine fibroids using a
procedure called uterine fibroid embolization, or UFE. The
Company's products continue to gain acceptance in this rapidly
emerging procedure, as well as in a number of other new and
established medical treatments.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, without limitation, statements regarding the
expected strategic importance and potential outcomes of the
Company’s QuadraSphere clinical trial and the potential benefits of
the Company’s marketing initiatives. The Company may use words such
as "plans," "seeks," "projects," "believes," "may," "anticipates,"
"estimates," "should," "intends," "looking forward," and similar
expressions to identify these forward-looking statements. These
statements are subject to risks and uncertainties and are based
upon the Company's beliefs and assumptions. There are a number of
important factors that may affect the Company's actual performance
and results and the accuracy of its forward-looking statements,
many of which are beyond the Company's control and are difficult to
predict, including, without limitation, risks relating to:
- the failure of the Company to
successfully develop, commercialize and achieve widespread market
acceptance of its products;
- the failure of the Company to
increase the rate of UFE procedures, and concomitant use of its
products for UFE, with its sales and marketing strategies;
- the failure of the Company to
achieve or maintain necessary regulatory approvals, either in the
United States or internationally, with respect to the development,
commercialization, manufacture and sale of its products and product
candidates, including, without limitation, the risk that the
Company will not gain necessary regulatory approvals to market and
sell its products in Japan through its agreement with Nippon
Kayaku;
- delays and/or adverse results in
the Company’s clinical trial using QuadraSphere loaded with
doxorubicin for the treatment of primary liver cancer;
- the Company’s ability to obtain
and maintain patent and other proprietary protection for its
products and product candidates;
- the absence of, or delays or
cancellations of, product orders;
- delays, difficulties or
unanticipated costs in the introduction of new products;
- competitive pressures;
- the risk of adverse outcomes in
product liability claims against the Company;
- the inability of the Company to
successfully execute on its plans and strategies for future growth,
including its plans to grow its business in both the UFE and
interventional oncology fields and its plans for international
growth;
- the inability of the Company to
raise additional funds in the near term to finance the development,
marketing, and sales of its products;
- general economic and market
conditions, both domestic and abroad; and
- risk factors described in the
section titled "Risk Factors" in the Company's Annual Report on
Form 10-K for the year ended December 31 2008 and the Form 10-Q for
the quarter ended June 30, 2009, each as filed by the Company with
the Securities and Exchange Commission, and described in other
filings made by the Company from time to time with the Securities
and Exchange Commission.
In addition, the forward-looking statements included in this
press release represent the Company’s estimates as of the date of
this release. The Company anticipates that subsequent events and
developments may cause its forward-looking statements to change.
The Company specifically disclaims any obligation or intention to
update or revise these forward-looking statements as a result of
changed events or circumstances after the date of this press
release.
BioSphere Medical,
Inc.SELECTED FINANCIAL INFORMATION
CONSOLIDATED CONDENSED BALANCE
SHEETSAs of September 30, 2009 and December 31,
2008(in thousands, unaudited)
September 30, December 31,
2009 2008 ASSETS Cash, cash equivalents and
investments $ 18,566 $ 18,239 Accounts receivable, net 4,714 4,729
Inventories 3,749 3,762 Prepaid expenses and other current assets
689 663 Property and equipment, net 897 989 Goodwill 1,443 1,443
Other assets 510 403 Total assets $ 30,568 $
30,228 LIABILITIES AND STOCKHOLDERS' EQUITY Accounts payable
and accrued expenses $ 6,042 $ 5,402 Deferred revenue 847 63
Capital lease obligations 10 17 Stockholders' equity 23,669
24,746 Total liabilities and stockholders' equity $
30,568 $ 30,228
CONSOLIDATED CONDENSED STATEMENTS OF
OPERATIONS For the three and nine months ended September 30,
2009 and 2008 (in thousands, except per share amounts,
unaudited) Three
Months Ended Nine Months Ended September 30,
September 30, 2009 2008 2009
2008 Revenues $ 7,686 $ 7,198 $ 23,081 $ 22,023
Costs and expenses: Cost of revenues 1,851 1,889 5,606 5,922
Research and development 765 822 2,455 2,239 Sales 2,497 2,497
7,838 7,763 Marketing 1,287 1,855 4,111 4,872 General and
administrative 1,782 1,609 5,381 4,917 Patent 199
151 576 553 Total
costs and expenses 8,381 8,823
25,967 26,266 Loss from operations (695
) (1,625 ) (2,886 ) (4,243 ) Other income and expenses, net
(126 ) 356 (99 ) 413
Net loss before income taxes (821 ) (1,269 ) (2,985 ) (3,830
) Income tax (provision) benefit 605 (129 )
605 (129 ) Net Loss (216 ) (1,398 ) (2,380 )
(3,959 ) Preferred stock dividends (145 ) (145
) (434 ) (434 ) Net loss applicable to common
stockholders $ (361 ) $ (1,543 ) $ (2,814 ) $ (4,393 ) Net
loss per common share Basic and diluted $ (0.02 ) $ (0.09 ) $ (0.16
) $ (0.24 ) Weighted average common shares outstanding Basic
and diluted 18,057 17,990 18,035
17,977
Biosphere Medical (MM) (NASDAQ:BSMD)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Biosphere Medical (MM) (NASDAQ:BSMD)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024